Imago BioSciences is a clinical-stage biotechnology company developing treatments for myeloid diseases. It conducts research in bone marrow disease prevention and treatment, including acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis, etc. The company focuses its research on an epigenetic enzyme, LSD1, for cancer therapy.